Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Clinical trials
Information about clinical studies is available at database of
News
-
2010-08-31 | Thrombosis
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study
2010-08-31 | Thrombosis
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study
Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more
-
2010-08-30 | Worldnews
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
2010-08-30 | Worldnews
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
Bayer’s dermatology subsidiary Intendis prepares to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction more
-
2010-08-04 | Thrombosis
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
2010-08-04 | Thrombosis
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010 more
-
2010-08-04 | Worldnews
FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging
2010-08-04 | Worldnews
FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging
Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging more
-
2010-07-29 | Bayer HealthCare
Bayer increases sales and earnings in the second quarter
2010-07-29 | Bayer HealthCare
Bayer increases sales and earnings in the second quarter
Sales grow by 14.6 percent to EUR 9,179 million / EBITDA before special items up 8.6 percent to EUR 1,917 million / Core earnings per share increase by 9.5 percent to EUR 1.15 / Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion / Group outlook confirmed for 2010 more



